CAMBRIDGE, Mass. , Oct. 1, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in the second cohort of a two-cohort randomized Phase 2 clinical trial of MM-121 in combination with paclitaxel in the neoadjuvant setting of
CAMBRIDGE, Mass. , Sept. 3, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy , President & CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013 at 10:00 a.m.
CAMBRIDGE, Mass. , Aug. 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted two separate orphan drug designations for its bispecific antibody, MM-111, for the
CAMBRIDGE, Mass. , July 25, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Second Quarter 2013 Investor Conference Call and webcast at 11 a.m., Eastern time , on Thursday, August 8 .
CAMBRIDGE, Mass. , July 17, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the closing of its sale of 5,750,000 shares of its common stock at a price to the public of $5.00 per share and $125,000,000 aggregate principal amount of its 4.50% convertible senior